Sulfaphenazole – 1 g

Brand:
Cayman
CAS:
526-08-9
Storage:
-20
UN-No:
Non-Hazardous - /

CYP2C9 is a major cytochrome P450 enzyme that is involved in the metabolic clearance of various therapeutic agents. Disruption of this enzyme’s activity can lead to adverse drug reactions.{24411} Sulfaphenazole is an inhibitor of CYP2C9 (Ki = 0.3 μM) that demonstrates at least 100-fold selectivity over other CYP450 isoforms (Kis = 63 and 29 μM for CYP2C8 and CYP2C18, respectively, and no activity at CYP1A1, CYP1A2, CYP3A4, CYP2C19).{24410,24408} At 10 μM, sulfaphenazole has been shown to inhibit endothelium-derived hyperpolarizing factor synthase, a CYP450 isozyme in the porcine coronary artery homologous to CYP2C8/9 that generates reactive oxygen species in coronary endothelial cells and modulates vascular tone and homeostasis.{24409}  

 

SKU: - Category:

Description

Selective inhibitor of CYP2C9 (Ki = 0.3 μM); inhibit endothelium-derived hyperpolarizing factor synthase, a CYP450 isozyme in the porcine coronary artery homologous to CYP2C8/9 that generates reactive oxygen species in coronary endothelial cells and modulates vascular tone and homeostasis


Formal name: 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide

Synonyms:  Depocid|Depotsulfonamide|Plisulfan|Raziosulfa

Molecular weight: 314.4

CAS: 526-08-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Ox Stress Reagents|Antioxidants||Product Type|Biochemicals|Small Molecule Inhibitors|Cytochrome P450||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Research Area|Cardiovascular System|Vasculature